^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:midostaurin (Multi-tyrosine kinase inhibitor) +
    Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.

    Published date:
    05/26/2022
    Excerpt:
    A total of 23 patients received CPX-351 + MID and had sufficient data to be included in the analysis ...Preliminary results from the V-FAST trial suggest CPX-351 + MID is feasible, with a manageable safety profile and promising remission rates in adults with newly diagnosed AML who have a FLT3 mutation.
    DOI:
    10.1200/JCO.2022.40.16_suppl.7043
    Trial ID:
    V-FAST master